Sign Up Now!
To sign up for our newsletter or print publications, please enter your contact information below.
First Name *
Last Name *
Email Address (Verify) *
We will request your mailing address on the next page.
We will request your mailing address on the next page.

Retrospective Analysis Provides Insight into Treatment-Emergent Neutropenia Among Patients with Metastatic Breast Cancer Treated with Ribociclib or Palbociclib

2020 Year in Review - Breast Cancer - Breast Cancer

Real-world data showed that patients with metastatic breast cancer receiving palbociclib had a numerically higher rate of neutropenia than patients receiving ribociclib.

After the administration of CDK4/6 inhibitors ribociclib and palbociclib for hormone receptor–positive metastatic breast cancer, neutropenia is the most common adverse event.

In patients receiving these therapies, data are lacking to compare the incidences of treatment-emergent neutropenia. Lee Schwartzberg, MD, FACP, Medical Oncologist, Breast Cancer, West Cancer Center & Research Institute, Germantown, TN, and colleagues presented real-world data exploring the incidence, duration, and severity of treatment-emergent neutropenia, based on a retrospective analysis of administrative claims and electronic health records.

Two mutually exclusive cohorts of patients with metastatic breast cancer were treated with ribociclib or palbociclib. Patients were matched 1:1 based on year of treatment start and age. Previous baseline activity was required for ≥6 months.

To evaluate incidence rates of treatment-emergent neutropenia from January 1, 2015, to December 31, 2018, in patients receiving ribociclib or palbociclib, the MarketScan claims databases were used. From the Optum deidentified Electronic Health Record Dataset, data on neutropenia severity and duration were acquired. Neutrophil counts from lab tests (grade 1/2, 1000-1500/µL; grade 3, 500-1000/µL; grade 4< 500/µL) within the first 180 days of treatment were used to grade neutropenia severity. Kaplan-Meier analysis was used to estimate the duration of neutropenia, characterized as the period of time between first aberrant laboratory result and those showing resolution. One hundred fifty-two patients from the MarketScan database were included in the ribociclib and palbociclib groups after 1:1 matching, and 168 matched patients from the Optum database were also included.

In 38 (25%) patients in the palbociclib group and 25 (17%) patients in the ribociclib group, neutropenia was reported. The rate of neutropenia per person-treatment year was higher in the palbociclib group at 0.5 (95% confidence interval [CI], 0.4-0.7) when compared with the ribociclib group at 0.4 (95% CI, 0.3-0.6).

Although statistical significance was not demonstrated due most likely to small sample size, neutropenia rate ratio between treatments (palbociclib vs ribociclib) was 1.4 (95% CI, 0.8-2.3). Whereas the severity of neutropenia with palbociclib and ribociclib was similar at 32% for grade 1/2 and 4% for grade 4, it differed at grade 3, which was 35% for palbociclib and 26% for ribociclib. For grade 3 or 4 neutropenia (palbociclib vs ribociclib), the rate ratio was 1.3 (95% CI, 0.9-1.8). For palbociclib compared with ribociclib, the median neutropenia duration was significant, at 29 days compared with 20 days (P <.01).

Considering best possible practices for the management of neutropenia is an integral component of the treatment of hormone receptor–positive metastatic breast cancer. Clinicians may want to consider the impact of treatment and real-world data regarding rates of neutropenia, especially a higher rate of grade 3 neutropenia and a longer duration of neutropenia in patients receiving palbociclib therapy.

Source: Schwartzberg LS, Zarate JP, Chandiwana D, et al. Real-world incidence, duration, and severity of treatment-emergent (TE) neutropenia among patients (pts) with metastatic breast cancer (MBC) treated with ribociclib (RIB) or palbociclib (PAL). J Clin Oncol. 2020;38(15_suppl). Abstract e13048.

Related Items
Low-Dose Capecitabine Maintenance Therapy Improves Survival in Patients with Triple-Negative Breast Cancer
Robert J. Ignoffo, PharmD, FASHP, FCSHP, FHOPA
JHOP - April 2021 Vol 11, No 2 published on April 27, 2021 in From the Literature, Breast Cancer, Dose Escalation/Reduction
FDA Approves Margenza for Treatment of Metastatic HER2-Positive Breast Cancer
Web Exclusives published on March 2, 2021 in Breast Cancer, FDA Updates
FDA Approves Margenza for the Treatment of Metastatic HER2-Positive Breast Cancer
JHOP - February 2021 Vol 11, No 1 published on February 22, 2021 in FDA Updates, Breast Cancer
Breast Cancer Year in Review Introduction
2020 Year in Review - Breast Cancer published on January 24, 2021 in Breast Cancer
Concurrent Use of Medications with Potential Drug–Drug Interactions: Real-World Analysis of Patients Treated with CDK4/6 Inhibitors
2020 Year in Review - Breast Cancer published on January 24, 2021 in Breast Cancer
Abemaciclib plus Fulvestrant Provides Statistically Significant Benefit as First- and Second-Line Therapy for Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer
2020 Year in Review - Breast Cancer published on January 24, 2021 in Breast Cancer
Preliminary Results from a Phase 2 Trial of Fulvestrant/Palbociclib as First-Line Therapy in Postmenopausal Women with Hormone Receptor–Positive, HER2-Negative Endocrine-Sensitive Advanced Breast Cancer
2020 Year in Review - Breast Cancer published on January 24, 2021 in Breast Cancer
Ribociclib Added to Endocrine Therapy in Patients with Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer Demonstrated Favorable Quality-of-Life Results
2020 Year in Review - Breast Cancer published on January 24, 2021 in Breast Cancer
Examining Different Sequence Effects of CDK4/6 Inhibitor Combinations on Actual Real-World Outcomes of Treatment in Patients with Hormone Receptor–Positive and HER2-Negative Metastatic Breast Cancer
2020 Year in Review - Breast Cancer published on January 24, 2021 in Breast Cancer
Benefit of Alpelisib When Combined with Fulvestrant as Demonstrated Through Biomarker Subanalysis from the SOLAR-1 Study
2020 Year in Review - Breast Cancer published on January 20, 2021 in Breast Cancer
Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.